Thyronorm 5 mg/ml Oral Solution for Cats

দেশ: যুক্তরাজ্য

ভাষা: ইংরেজি

সূত্র: VMD (Veterinary Medicines Directorate)

সক্রিয় উপাদান:

Thiamazole

থেকে পাওয়া:

Norbrook Laboratories Limited

এটিসি কোড:

QH03BB02

INN (আন্তর্জাতিক নাম):

Thiamazole

ফার্মাসিউটিকাল ফর্ম:

Oral solution

প্রেসক্রিপশন টাইপ:

POM-V - Prescription Only Medicine – Veterinarian

থেরাপিউটিক গ্রুপ:

Cats

থেরাপিউটিক এলাকা:

Anti Hormone Agent

অনুমোদন অবস্থা:

Authorized

অনুমোদন তারিখ:

2016-06-03

পণ্য বৈশিষ্ট্য

Revised: July 2021
AN: 01038/2020
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Thyronorm 5 mg/ml Oral Solution for Cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Thiamazole
5 mg
EXCIPIENT:
Sodium Benzoate (E211)
1.5 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral solution
An off-white to light yellow opaque solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the stabilisation of hyperthyroidism in cats prior to surgical
thyroidectomy.
For the long term treatment of feline hyperthyroidism.
4.3
CONTRAINDICATIONS
Do not use in cats suffering from systemic disease such as primary
liver disease or
diabetes mellitus.
Do not use in cats showing signs of autoimmune disease.
Do not use in animals with disorders of white blood cells, such as
neutropenia and
lymphopenia.
Do not use in animals with platelet disorders and coagulopathies
(particularly
thrombocytopenia).
Do not use in pregnant or lactating females. Please refer to section
4.7.
Revised: July 2021
AN: 01038/2020
Page 2 of 7
Do not use in known cases of hypersensitivity to the active substance
or to any of the
excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
In order to enhance stabilisation of the hyperthyroid patient the same
feeding and
dosing schedule should be used daily.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If more than 10 mg of thiamazole per day is required animals should be
monitored
particularly carefully.
Use of the product in cats with renal dysfunction should be subject to
careful
risk:benefit assessment by the clinician. Due to the effect thiamazole
can have on
reducing the glomerular filtration rate, the effect of therapy on
renal function should
be monitored closely as deterioration of an underlying renal
impairment may occur.
Haematology must be monitored due to risk of leucopenia or haemolytic
anaemia
before initiating treatmen